AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of formula (I), their stereoisomers, tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, and pharmaceutical compositions containing them.



(I)

wherein

R_1 represents hydrogen, linear or branched, substituted or unsubstituted groups selected from (C_1-C_{12}) alkyl, (C_2-C_{12}) alkenyl, (C_2-C_{12}) alkynyl, (C_3-C_{12}) cycloalkyl; substituted or unsubstituted grups selected from aryl, heteroaryl or heterocyclic groups; R_2 is selected from hydrogen, -OBF_2 or -OR_6,

Where R_6 represents hydrogen, (C_1-C_6) alkyl, (C_3-C_6)alkenyl or (C_3-C_{-6})alkynyl groups, which may optionally be substituted; R_3 represents H, OH, linear or branched, substituted or unsubstituted groups selected from -O(C_1-C_{12}) alkyl, -O(C_2-C_{12})alkenyl,-O(C_2-C_{12}) alkynyl, halo, NO_2, CN, or NR'R" groups, where R'R" may be same or different and independently represent H, linear or branched, substituted or unsubstituted groups selected from (C_1-C_6) alkyl, (C_2-C_6 alkynyl or acyl groups; R_4 repesents H or halogen atom; X represents N or C-R_7, where R_7 represents H, -OH, -(O_n(C_1-C_6)

substituted or unsubstituted alkyl where n is 0 or 1, $-NO_2$, $-NH_2$, $-NHCOCH_3$, -CN, -COOH groups; R_1 and R_7 can be taken together with the atoms to which they are attached to form a cyclic ring, which may optionally be substituted and may also optionally contain from 1 to 3 heteroatoms selected from O, N and S;

Ra, Rb may be same or different and represents hydrogen, halogen, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, hydroxy, thio, amino, nitro, cyano, formyl, or substituted or unsubstituted groups selected from linear or branched (C_1-C_{12}) alkyl, linear or branched (C_1-C_{12}) alkenyl, linear or branched (C_1-C_{12}) alkynyl, (C_3-C_7) cycloalkyl, (C_3-C_7) cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C_1-C_{12}) alkoxy, (C_1-C_{12}) alkenoxy, cyclo(C_3-C_7)alkoxy, aryl, aryloxy, aralkyl, ar(C_1-C_{12})alkoxy, heterocyclyl, heteroaryl, heterocyclyl(C_1-C_{12})alkyl, heteroar (C_1-C_{12}) alkyl, heteroaryloxy, heteroar(C_1-C_{12})alkoxy, heterocycloxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, mono-substituted or di-substituted amino, arylamino, aralkylamino, carboxylic acid and its esters and amides, hydroxyalkyl, aminoalkyl, mono-substituted or di-substituted aminoalkyl, alkoxyalky, aryloxyalkyl, aralkoxyalkyl, (C_1-C_{12})alkylthio, thio(C-C_{12})alkyl, arylthio, (C_1-C_{12})alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarboylamino, alkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hydrazine, alkyl hydrazine, alkoxyamino, hydroxylamino, sufenyl and sulfonyl groups, sulfonic acid, phosphonic acid; R_c & R_d may be same or different and represents hydrogen, substituted or unsubstituted groups

selected from alkyl, alkenyl groups; Z represents O, S or NH, which may optionally be substituted;

2. (Previously Presented) A compound as claimed in claim 1 wherein the substituents on R_1, R_2, R_3, R_6, R_7, R', R", X, Ra, Rb, Rc & Rd are selected from hydroxyl, oxo, halo, thio, nitro, amino, cyano, formyl, amidino, guanidine, hydrazino, alkyl, haloalkyl, perthaoloalkyl, alkoxy, haloalkoxy, perhaloalkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, alkoxy, alkenoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocylyl, heteroaryl, heterocyclyalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclyloxy, heterocyclylalkoxy, heterocyclylalkoxyacyl, acyl, acyloxy, acylamino, monosubstituted or disubstituted amino, arylamino, aralkylamino, carboxylic acid and its derivatives such as esters and amides, carbonylamino, hydroxyalkyl, aminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, arylthio, alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, alkoxyamino, hydroxyl amino, sulfenyl derivatives, sulfonyl derivatives, sulfonic acid and its derivatives, phosphonic acid and its derivatives.

3. (Previously Presented) A compound as claimed in claim 1 wherein R_2 represents -OBF2 or -OH group.

4. (Currently Amended) A compound according to claim 1 which is selected from: 1-Cyclopropyl-6-fluoro-8-methoxy-7-(2-nitro-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts; 1-Cyclopropyl-6-fluoro-8-methoxy-7-(2-nitro-6,7-dihydro-4H-thieno[3.2-c]pyridine-5-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid and its pharmaceutically acceptable salts; 1-

Cyclopropyl-7-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts;

1-Cyclopropyl-7-(6,7-dihydro4H-thieno[3,2-c]pyridine-5-yl)-6-fluoro-8-~~mehtoxy~~methoxy -4-oxo-1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts;

1-Cyclopropyl-7-(6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts;

1-Cyclopropyl-6-fluoro-8-methoxy-7-(7-methyl-6, 7-dihydro-4H- thieno[3,2-c]pyridine-5-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid and its pharmaceutically acceptable salts;

1-Cyclopropyl-6-fluoro-7-(2-jydroxymethyl-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-y)-8-methoxy-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid and its pharmaceutically acceptable salts;

1-Cyclopropyl-7-(2-formyl-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-5,6,8-trifluoro-4-oxo1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts;

1-Cyclopropyl-7-(2-nitro-6,7-dihydro-4H-thieno[3,2-c]pyridine-5-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydro-quinoline-3-carboxy fluoroborate and its pharmaceutically acceptable salts;

1-Cyclopropyl-7-(2-nitro-6,7-dihydro-4H-thieno[3,2-c] pyridine-5-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid and its pharmaceutically acceptable salts.

5. (Currently Amended) A composition comprising a compound of formula (I) as defined in ~~any preceding claims~~ claim 1 or a therapeutically acceptable salt thereof, and a therapeutically acceptable excipient.

6. (Previously Presented) A pharmaceutical composition, which comprises a compound as defined in claim 5, and a pharmaceutically acceptable carrier, diluents or excipients or solvate.

7. (Currently Amended) A pharmaceutical composition according to claim 5~~ and 6~~, in the form of tablets, pills, capsules, powder, granules, syrup, solution or suspension.

8. (Currently Amended) A method for treating infections comprising administering a therapeutically acceptable amount of compound of formula (I) as defined in ~~any preceding claim~~claim 1, or a therapeutically acceptable salt thereof.

9. (Currently Amended) A method for treating an infection caused by gram-positive organisms, gram-negative organisms, mycobacterial infections or nosocomial infections comprising administering an effective amount of a compound according to ~~any preceding claims~~claim 1 to a mammal in need thereof.

10. (Currently Amended) The method as claimed in ~~claims 8 and 9~~claim 8 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

11. (Currently Amended) Use of the compounds as claimed in ~~any preceding claims~~claim 1 or their pharmaceutically acceptable salts for the preparation of medicine suitable for the treatment of infection caused by gram-positive organisms, gram-negative organisms, mycobacterial infections or nosocomial infections.

12. (Previously Presented) A process for the preparation of a compound of formula (I) as defined in claim 1, where all symbols are as defined earlier, and including their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, which comprises:

i) converting a compound of formula (II) to compound of formula (III)



ii) reacting a compound of formula (III) with a compound of formula (IV) to obtain (V)



iii) converting the compound of formula (V) to compounds of formula (I)

Where Ra, Rb, Rc, Rd, R_1, R_3 & R_4 are as described elsewhere in the specification and R_2 = -OBF_2, -OH.